Literature DB >> 19100796

Extrudable core system: development of a single-layer osmotic controlled-release tablet.

Kenneth C Waterman1, Bruce C MacDonald, Michael C Roy.   

Abstract

A new controlled-release, extrudable core system (ECS) tablet has been developed which osmotically delivers high doses of low solubility active pharmaceutical ingredients (API's). The tablet has a single core formed in a modified oval shape with a semi-permeable coating. The core contains hydroxyethylcellulose, which serves to entrain the API particles as they are extruded out a hole in the coating at one end of the tablet, and a sugar, which provides the osmotic driving force for water imbibing. The dosage form has been successfully shown to control delivery of API over a range of delivery rates even with 50% of the tablet being API (up to about 500 mg).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100796     DOI: 10.1016/j.jconrel.2008.11.017

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

1.  Floating elementary osmotic pump tablet (FEOPT) for controlled delivery of diethylcarbamazine citrate: a water-soluble drug.

Authors:  Zulfequar Ahamad Khan; Rahul Tripathi; Brahmeshwar Mishra
Journal:  AAPS PharmSciTech       Date:  2011-10-04       Impact factor: 3.246

2.  Alleviating the Influence of Circadian Rhythms and Drug Properties to the Release of Paliperidone Gel Matrix Tablets with Compression Coating Technology and Microenvironment Shaping.

Authors:  Zherui Zhang; Shumin Chen; Man Wen; Haibing He; Yu Zhang; Tian Yin; Jingxin Gou; Xing Tang
Journal:  AAPS PharmSciTech       Date:  2022-08-16       Impact factor: 4.026

3.  Asymmetric Membrane Capsules for Extended Delivery of the Weakly Basic Drug Carvedilol.

Authors:  Kumar Guarve; Ghanshyam Das Gupta
Journal:  Pharmaceutics       Date:  2010-05-18       Impact factor: 6.321

4.  Feasibility of optimizing trimetazidine dihydrochloride release from controlled porosity osmotic pump tablets of directly compressed cores.

Authors:  Basant A Habib; Randa T Abd El Rehim; Samia A Nour
Journal:  J Adv Res       Date:  2013-06-11       Impact factor: 10.479

5.  Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.

Authors:  Yoshiya Tanaka; Naonobu Sugiyama; Shigeyuki Toyoizumi; Tatjana Lukic; Manisha Lamba; Richard Zhang; Connie Chen; Thomas Stock; Hernan Valdez; Christopher Mojcik; Haiyun Fan; Chenhui Deng; Hirotoshi Yuasa
Journal:  Rheumatology (Oxford)       Date:  2019-01-01       Impact factor: 7.580

6.  Design, Development, and Optimization of Sterculia Gum-Based Tablet Coated with Chitosan/Eudragit RLPO Mixed Blend Polymers for Possible Colonic Drug Delivery.

Authors:  Bipul Nath; Lila Kanta Nath
Journal:  J Pharm (Cairo)       Date:  2012-11-25

7.  Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.

Authors:  Manisha Lamba; Rong Wang; Tracey Fletcher; Christine Alvey; Joseph Kushner; Thomas C Stock
Journal:  J Clin Pharmacol       Date:  2016-11       Impact factor: 3.126

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.